Tempus AI is part of the Tempus group, and Sophia Genetics partners with AstraZeneca while Tempus collaborates with Boehringer Ingelheim on cancer therapies.
3 reports, 2 independent
Updated Aug 19
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 5
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Tempus AI is part of the Tempus group, and Sophia Genetics partners with AstraZeneca while Tempus collaborates with Boehringer Ingelheim on cancer therapies.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- AstraZeneca and SOPHiA GENETICS announced a collaboration to develop companion diagnostics.Sub-event
- Tempus AI and AstraZeneca announced a foundational model partnership.Sub-event
Multiple new collaborations announced between Tempus, Sophia Genetics, AstraZeneca, and Boehringer Ingelheim.1 source
Tempus AI confirmed as part of Tempus group; received FDA clearance for ECG-Low EF software.1 source
- Collaboration on AI platforms for cancer and Alzheimer's research, gaining inclusion in Russell indices.
Keep exploring
The entities involved
-
Tempus
biotechnology company based in Chicago, Illinois
-
AstraZeneca
British-Swedish pharmaceutical company
-
Sophia Genetics
Health technology company
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksStrategic Partnerships Power Tempus AI's Healthcare Expansion Tempus AI, Inc. TEM is rapidly expanding its partnerships across oncology and neuroscience, leveraging its AI platforms — Lens and Next —
- Simply Wall St.Tempus AI (TEM) Secures FDA Clearance For ECG-Low EF Software Tempus AI recently secured FDA clearance for its Tempus ECG-Low EF software and expanded its collaboration with Personalis for colorectal
- Unknown outlet